Show simple item record

dc.contributor.authorLópez, Daniel 
dc.contributor.authorBarriga, Alejandro 
dc.contributor.authorLorente, Elena 
dc.contributor.authorMir-Gerrero, Carmen 
dc.date.accessioned2020-01-15T12:50:54Z
dc.date.available2020-01-15T12:50:54Z
dc.date.issued2019-04-10
dc.identifier.citationJ Clin Med. 2019 Apr 10;8(4). pii: E486.es_ES
dc.identifier.issn2077-0383es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8893
dc.description.abstractAccurate antiviral humoral and cellular immune responses require prior recognition of antigenic peptides presented by human leukocyte antigen (HLA) class I and II molecules on the surface of antigen-presenting cells. Both the helper and the cytotoxic immune responses are critical for the control and the clearance of human respiratory syncytial virus (HRSV) infection, which is a significant cause of morbidity and mortality in infected pediatric, immunocompromised and elderly populations. In this article we review the immunoproteomics studies which have defined the general antigen processing and presentation rules that determine both the immunoprevalence and the immunodominance of the cellular immune response to HRSV. Mass spectrometry and functional analyses have shown that the HLA class I and II cellular immune responses against HRSV are mainly focused on three viral proteins: fusion, matrix, and nucleoprotein. Thus, these studies have important implications for vaccine development against this virus, since a vaccine construct including these three relevant HRSV proteins could efficiently stimulate the major components of the adaptive immune system: humoral, helper, and cytotoxic effector immune responses.es_ES
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Economy grants BIO2011-25636 and SAF2014-58052 and “Acción Estratégica en Salud 2018”.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAntigen processinges_ES
dc.subjectHLAes_ES
dc.subjectT cellses_ES
dc.subjectimmune responsees_ES
dc.subjectimmunoproteomicses_ES
dc.subjectmass spectrometryes_ES
dc.subjectrespiratory infectious diseasees_ES
dc.subjectvaccinees_ES
dc.titleImmunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Designes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID30974886es_ES
dc.format.volume8es_ES
dc.format.number4es_ES
dc.format.page486es_ES
dc.identifier.doi10.3390/jcm8040486es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/jcm8040486es_ES
dc.identifier.journalJournal of clinical medicinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BIO2011-25636es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2014-58052es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional